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Abstract 
The transmissible spongiform encephalopathies, which include Creutzfeldt-Jakob disease, are
fatal neurodegenerative disorders caused by the pathological accumulation of abnormal prion
protein. The diagnosis of Creutzfeldt-Jakob disease is complex. The electroencephalogram,
magnetic resonance imaging, lumbar puncture and genetic testing findings can help in the
differential diagnosis of rapidly progressive dementia. There has recently been considerable
debate  as  to  whether  proteins  involved in  the development  of  neurodegenerative  diseases
should  be  regarded  as  prions  or  only  share  prion-like  mechanisms.  Two  recent  reports
described the detection of abnormal prion protein in the nasal mucosa and urine of patients
with  Creutzfeldt-Jakob  disease.  These  findings  raise  major  health  concerns  regarding  the
transmissibility of human prion diseases. We set out to address this neurological hot topic and
to draw conclusions on the basis of what is known in the literature thus far.




Human prion diseases, also known as transmissible spongiform encephalopathies, are a group
of  rare,  invariably  fatal  progressive  neurodegenerative  disorders  that  affect  mammalian
species [1]. With the present review, we intended to address several aspects of the human
prion diseases. 
One of the aims was to survey the possibilities of the diagnosis of Creutzfeldt-Jakob disease
(CJD), and to present a concise description of recent studies that detected pathological prion
protein in the nasal mucosa and urine of CJD patients. These findings raise new health care
concerns.  We additionally set out to address a hot topic in neurology, i.e.  whether or not
neurodegenerative diseases (NDs) should be regarded as prionopathies. 
2. Aetiology
Human prion diseases can be divided into three aetiological groups: sporadic, genetic and
acquired.  Sporadic CJD (sCJD),  the most  frequent  form of prion diseases,  has an annual
mortality rate of 1 to 1.5 per million [2]. The genetic prion diseases, which are related to
mutation  of  the  prion  protein  gene  (PRNP)  on  human  chromosome  20,  account  for
approximately  5-15%  of  all  prion  diseases  worldwide  [3].  On  the  basis  of  their
clinicopathological  features  they  can  be  divided  into  genetic  CJD  (gCJD),  Gerstmann-
Straussler-Scheinker  disease  and fatal  familial  insomnia [4].  The acquired forms of  prion
diseases include iatrogenic CJD (iCJD), due to medical interventions, variant CJD (vCJD),
related to bovine spongiform encephalopathy (BSE), and kuru [5]. They are responsible for 2-
5% of all prion diseases.
3. The prion protein
The word prion is short for proteinaceous infectious particle, implying that prions contain
only amino acids [6]. Under physiological conditions, prion protein is found on the surface of
cells (this form is abbreviated as PrPc), attached to the outer part of the bilipid layer of the cell
membranes  through  a  glycophosphoinositol  (GPI)  anchor  [7].  The  precise  physiological
function  of  PrPc  remains  to  be  elucidated.  Studies  have  suggested  that,  through  signal
transductional pathways, it might have a prominent role in embryogenesis, the activation and
differentiation of lymphocytes, the reproduction of haematopoetic stem cells, neuritogenesis
and neuronal differentiation [8-15]. In structure, PrPc  is comprised mainly of alpha-helices
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[16].  On the other  hand, the pathological  form of the protein (PrP sc,  where sc  stands for
scrapie) consists mostly of beta-sheets [17]. The misfolding of PrPc to PrPsc has a devastating
effect on the central nervous system (CNS). The initial misfolding of the physiological protein
can occur spontaneously (in sCJD) or it can be inherited (in gCJD). PrPsc can also enter the
CNS through protein ingestion (via the consumption of the meat of cattle with BSE) or by
iatrogenic  means  (i.e.  dura  mater  or  corneal  grafts).  Once  developed,  PrPsc serves  as  a
template and can change the conformation of the physiological PrPc in such a way that it will
be misfolded into PrPsc. This process is known as autocatalytic conversion [18]. Abnormal
prions can aggregate and form soluble oligomers [19]. Increasing quantities of PrPsc attach to
one another and form insoluble polymers, which then make up amyloid fibres. The polymers
may also  break,  thereby providing  more  nuclei  for  PrPc to  misfold  into  PrPsc.  Figure  1
schematically illustrates the misfolding of PrPc into PrPsc.
The  accumulation  of  aberrant  prion  proteins  inside  neurons  will  eventually  lead  to
programmed cell  death (apoptosis). Misfolded proteins are normally degraded in cells via
proteosomes or autolysomes [19]. However, PrPsc can evade these clearance pathways and
accumulate in cells. It remains unclear exactly how PrPsc aggregates exert neurotoxic effects.
A small number of mechanisms have been proposed which, individually or acting in parallel,
can lead to programmed cell death [20]. PrPc has been demonstrated to have a neuroprotective
effect [21]. The conformational change of the protein may therefore lead to increased levels of
oxidative  and  endoplasmic  reticulum  stress.  Moreover,  overloading  and  the  consequent
dysfunction of the ubiquitin-proteosome and endosome-lysosomal systems by accumulated
PrPsc could induce apoptosis. Another theory postulates that the loss of function of PrPc might
play  a  significant  role  in  the  synaptic  alterations  and  dendritic  atrophy  observed  in
transmissible  spongiform encephalopathies.  The  exact  signal  transductional  pathways  and
proteins involved in the above-mentioned apoptosis-inducing mechanisms have not yet been
elaborated. 
PrPsc has the further characteristic attribute that it can propagate from cell to cell. Autopsies
on patients who died from transmissible spongiform encephalopathy have demonstrated that
PrPsc is found throughout the brain. The pathological form of the protein can be transmitted
between individuals, and also between species. The consumption of the meat of cattle infected
with BSE caused a major epidemic in Great Britain not too long ago [22]. 
The main characteristics of prion proteins are summarized in Table 1.
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4. The prion hypothesis of neurodegenerative diseases
Parkinson’s  disease  (PD),  degenerative  parkinsonisms,  Alzheimer’s  disease  (AD),
Huntington’s disease (HD) and amyotrophic lateral  sclerosis (ALS) are all  NDs, and they
share  some  common  pathomechanisms.  These  include  glutamate-induced  excitotoxicity,
impaired  Ca2+  homeostasis,  the  production  of  reactive  oxygen  species,  a  mitochondrial
dysfunction, neuroinflammation and an altered tryptophan metabolism [23-26]. Our research
group  has  investigated  the  roles  of  neuroactive  kynurenines  in  various  NDs.  The  key
components  of  the  tryptophan  degradation  pathway  include  kynurenic  acid  (KYNA),  3-
hydroxy-L-kynurenine  and  quinolinic  acid.  KYNA  has  been  demonstrated  to  have
neuroprotective  effects,  whereas  the  latter  two  are  neurotoxic  compounds  [27].  An
unfavourable  shift  in  the  degradation  pathway  of  tryptophan  can  therefore  promote
neurotoxicity and exert deleterious effects on the neurones. 
The accumulation of aberrant, misfolded proteins in the CNS can also play a pivotal role in
the development of NDs. Recent findings provide evidence that the proteins responsible for
the above-mentioned diseases share prion-like mechanisms [28-32]. In this paragraph, we did
not aim to give a critical opinion, instead we set out to summarize the research done in this
topic. 
4.1 Parkinson’s disease 
The pathological hallmark of PD is the presence of misfolded α-synuclein (α-syn) aggregates
in certain areas of the brain. Similarly to PrPc, α-syn is normally present in an α-helix-rich
form, but misfolds into a structure characterized by β-sheets [33,34]. The phosphorylated and
ubiquitinated forms of α-syn aggregate via autocatalytic conversion and form Lewy bodies
[35].  Braak et  al.  demonstrated  that  the  Lewy bodies  are  initially present  in  the  anterior
olfactory nucleus and dorsal motor nucleus of the vagal nerve [36,37]. The pathology then
spreads towards the rostral areas of the brain, including the substantia nigra, and by the end
stage of the disease, α-syn aggregates have even developed in certain cortical areas. 
The propagation of α-syn pathology raises the question of whether α-syn can spread from cell
to  cell  in  a  PrPsc-like  manner.  Autopsy  studies  have  revealed  that,  12-16  years  after
transplantation, Lewy bodies are present in the grafted-embryonic mesencephalic neurones in
PD patients  [28,29,38].  This  unequivocally indicated that  α-syn has  prion-like cell-to-cell
transmissibility. Furthermore, after injecting three different brain areas (the substantia nigra,
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the  striatum or  the  entorhinal  cortex)  of  wild-type  mice  with  recombinant  α-syn  fibrils,
Masuda-Suzukake  et  al.  found  that  propagation  of  the  phosphorylated  α-syn  pathology
affected different brain regions in direct or indirect contact with the initial injection site [39]. 
These observations support the hypothesis that α-syn spreads between interconnected brain
areas through axonal transport. The possible mechanisms of transmission of α-syn are still
unclear, but Mohamed et al. described several transmission routes for tau protein [40], which
might also apply to α-syn.
4.2 Alzheimer’s disease
Dementia is most commonly characterized by the presence of extracellular β-amyloid (Aβ)
fibrils  and intracellular  hyperphosphorylated tau polymers  forming neurofibrillary tangles.
Tau has a significant role in other NDs, i.e. progressive supranuclear palsy and corticobasal
degeneration, and it has been demonstrated that tau protein also participates in prion-like cell-
to-cell  propagation  [30,41].  Other  experiments  revealed  that  inoculation  with  abnormal
human tau or Aβ resulted in the presence of misfolded protein aggregates in the brains of
transgenic mice [42,43]. 
One  somewhat  astonishing  finding  has  supported  the  link  between  AD and  prionopathy.
Under  experimental  conditions,  extracellular  soluble  Aβ  oligomers  activated  PrPc  on  the
surface of hippocampal neurones [44]. PrPc bound Aβ oligomers as part of a multiprotein
receptor  complex that  includes  low-density lipoprotein  receptor-related  protein-1 as  a  co-
receptor  and requires  the  integrity of  cholesterol-rich  lipid  rafts  that  contain  the  receptor
complex in the cell membrane [45]. PrPc activation led to an increased function of Fyn kinase,
which induced tau hyperphosphorylation and also phosphorylation of the NR2B subunit of the
NMDA receptor,  through signal  transduction pathways [45-47].  Consequently,  the NMDA
receptor  was  activated  and  glutamate  excitotoxicity  became  more  pronounced.  This
eventually  led  to  cell  death  and  a  synaptic  dysfunction.  Although  these  findings  are
fascinating, they have not been inconclusively proven. Some experiments led to contradictory
results  regarding  the  connection  between  Aβ  and  PrPc [48-50].  It  has  additionally  been
demonstrated that Aβ displays neurotoxic effects in the absence of PrPc. 
PrPc has beneficial, neuroprotective effects. It can inhibit both the NMDA receptor and β-
secretase, thereby reducing excitotoxicity and the formation of Aβ [51,52]. α-Cleavage of PrPc
is  carried out directly or indirectly by the ADAMs (a disintegrin and metalloproteinases),
members  of  the  zinc-dependent  metalloproteinase  family  (more  specifically  ADAM8,
ADAM9, ADAM10 and ADAM17) [53,54]. α-Cleavage produces two fragments, N1 and C1.
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The N1 fragment can bind to Aβ and reduce aggregation and propagation of the aberrant
protein [55]. It also has a neuroprotective effect by inhibiting p53-mediated cell death [56].
Moreover, the C1 fragment can inhibit the formation of PrPsc [57]. 
These findings (similarly as in PD) support the hypothesis that tau and Aβ can spread between
cells.  The  available  findings  allow  the  conclusion  that  tau  and  Aβ  share  prion-like
mechanisms. 
4.3 Other neurodegenerative diseases
A number  of  studies  have  demonstrated  that  the  protein  huntingtin  exhibits  prion-like
behaviour in HD, as does superoxide dismutase-1 in ALS. These proteins are also prone to
misfold,  convert  normal  structured  proteins  to  abnormal  ones,  escape  cellular  clearance
pathways  and  aggregate  [31,32,58-60].  Cell-to-cell  propagation  has  likewise  been
demonstrated.  Tables 2 and 3 summarize the characteristics and prion-like attributes of the
proteins involved in the development of NDs.
5. Contradictory findings to the prion hypothesis of neurodegenerative diseases
Tables 1 and 3 reveal that the significant difference between prions and the proteins involved
in NDs is that prions can be transmitted. There is other evidence that prionopathies and NDs
are two different entities, e.g. the utterly different courses of the diseases. In CJD, the health
of the patients deteriorates rapidly and death follows within months after the onset of the
symptoms. In NDs, on the other hand, the disease course demonstrates a slow progression. It
takes years or even decades even for NDs to be fatal. 
Moreover,  the  pathological  findings  vary  greatly.  Prionopathies  are  characterized  by
spongiform changes,  presenting  as  microvacuoles  and  confluent  vacuoles  in  the  neuropil
[20,61].  Reactive  astrocytosis,  microglia  accumulation  and  atrophy  are  also  present.
Spongiform changes are not hallmark findings in NDs. Various brain regions are affected in
different NDs. In PD, for instance, the affected brain areas are the olfactory nuclei, the brain
stem including the substantia nigra, the basal prosencephalon, the mesocortex and eventually
the  neocortex  [36,37].  In  AD,  abnormal  protein  accumulation  is  most  apparent  in  the
entorhinal cortex, the limbic cortex and finally the isocortical areas [62,63]. Since different
brain regions are involved in each disease, the various diseases are characterized by different
symptoms and diagnostic findings. In consequence of their great variety, a detailed discussion
of these symptoms and findings is beyond the scope of this article. 
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6. Diagnosis of Creutzfeldt-Jakob disease 
6.1 Present practice
The diagnosis of CJD is complex. It is often based on the exclusion of other, more frequent
causes of rapidly progressive dementia. The definite diagnosis is neuropathological; in most
cases,  the  diagnosis  can  be  established with the  use  of  a  series  of  diagnostic  procedures
[64,65]. 
Besides  the  rapidly  progressive  dementia,  the  suspicion  of  the  diagnosis  of  CJD  should
always  be  raised  by  the  early  development  of  myoclonus,  the  visual  or  cerebellar
disturbances, the pyramidal or extrapyramidal features and akinetic mutism [66]. 
The electroencephalogram (EEG) may support the diagnosis, but the EEG findings alone are
not specific for CJD. Frontal intermittent non-peaked rhythmical delta activity is  generally
seen  in  the  early  phase  of  sCJD [67].  Periodic  synchronous  bi-  or  triphasic  sharp-wave
complexes are found in the terminal stage of sCJD, with a sensitivity of 64% and a specificity
of 91% [68].
In the clinical diagnosis of sCJD, magnetic resonance imaging (MRI) is essential. Meissner et
al. specified the cerebral cortical regions, the hippocampus, the basal ganglia, the thalamic
nuclei and the cerebellum as the frequently affected anatomical regions of the brain [69]. Zerr
et al. later concluded that high signal intensities in the caudate nucleus and putamen or in at
least two cortical regions (temporal-parietal-occipital) in the FLAIR or DWI sequences are
the MRI diagnostic criteria for sCJD [64]. These criteria are accepted and recommended by
the European MRI-CJD Consortium. The sensitivity and specificity of MRI has been found to
be 96% and 93%, respectively [70].
The  14-3-3  protein  concentration  of  the  cerebrospinal  fluid  (CSF)  is  usually  elevated
following neuronal  damage.  The  WHO guidelines  suggest  a  positive  CSF 14-3-3  protein
concentration as a criterion for probable sCJD [71]. An increased CSF 14-3-3 protein level
has high sensitivity and low specificity for the diagnosis of sCJD and gCJD cases [72].
Genetic prion diseases are associated with numerous disease-, geographic- and frequency-
specific PRNP mutations [65]. The E200K mutation is the most frequent mutation worldwide,
while other mutations (P105L, N171S or V180I) are rare [4]. The polymorphism of codon 129
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influences the phenotype [1,73]. As a positive family history is absent in a high proportion of
the cases, PRNP analysis can be used to differentiate between certain sCJD and all genetic
prion disease cases, and it may allow the early or pre-symptomatic diagnosis of genetic prion
diseases [4]. Table 4 summarizes the steps involved in the diagnosis of CJD.
6.2 Novel findings
In the past few years, possible novel methods have been put forward for the detection of CJD,
and  two  papers  have  raised  public  health  concerns  regarding  the  transmissibility  of  the
disease. 
The real-time quaking-induced conversion (RT-QuIC) is a method that allows the detection of
small  amounts  of  PrPsc through  the  formation  of  thioflavin  T (ThT)  fluorescent  amyloid
fibrils. This method was first used for the PrPsc detection in CSF with high sensitivity and
specificity for the diagnosis of sCJD [74-76].
Orrú et al. have demonstrated that the olfactory epithelium can be of vital importance in the
detection of sCJD and gCJD [77]. A study was conducted in which 2 samples were taken from
each participant, one from the olfactory epithelium and one from the CSF. The samples were
then analysed by RT-QuIC.
Positive RT-QuIC reactions were observed in 30 of 31 patients diagnosed with sCJD or gCJD.
In  the  control  groups,  no  positive  reactions  were  found.  That  study therefore  implies  an
estimated sensitivity of 97% and an estimated specificity of 100% for the RT-QuIC of nasal
brushing samples. In contrast, the corresponding figures for the CSF samples were 77% and
100% respectively. Moreover, the ThT detection of PrPsc amyloids from olfactory samples
required  50  hours,  whereas  CSF  sampling  needed  90  hours  [77].  It  may  therefore  be
concluded that  nasal  brushing is  a  superior  sampling technique for  the detection of  CJD,
rather  than examinations on the CSF. However,  further  studies  are  warranted to  establish
whether this novel technique is advantageous for the clinical diagnosis of the various forms of
CJD.
In another recently published study, Moda et al. demonstrated that the urine of patients with
vCJD also contains low amounts of PrPsc, which can be detected even when the patients are in
the presymptomatic phase of the disease [78]. The urine of healthy subjects and of patients
with  vCJD,  sCJD,  gCJD,  or  other  neurodegenerative  and  non-degenerative  neurological
disorders,  was  analysed  by  a  protein  misfolding  cyclic  amplification  (PMCA)  method,
followed by proteinase K treatment and Western blotting (WB). With the PMCA method, a
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small amount of PrPsc can be amplified (similarly as with RT-QuIC), allowing the detection of
the aggregates by WB. 13 of the 14 urine samples from patients with vCJD proved to contain
PrPsc. No other positive reactions were observed. It was therefore concluded that with this
technique PrPsc can be unambiguously detected in the urine of patients with vCJD. PMCA and
WB showed an estimated sensitivity of 93% and an estimated specificity of 100% in this
study [78].  The peripheral tissues of patients with the infectious form of CJD were earlier
demonstrated to contain more PrPsc than those of patients with gCJD or sCJD [79-81]. 
7. Conclusions
Although proteins share prion-like mechanisms in NDs, as long as their transmissibility is not
proven they should not be regarded as prionopathies. Clinical, diagnostic and pathological
findings also support the distinction between NDs and prionopathies. However, this current
hot topic in neurology should remain under scrutiny until sufficient evidence is available to
demonstrate quite clearly either the prion-like or the non-prion-like behaviour of NDs. 
The presence of PrPsc in the olfactory mucosa raises the question of whether CJD can be
transmitted between humans through nasal discharges. Animal models have shown that the
nasal and airborne transmission of prion disease is possible [82-86]. However, no cases of the
airborne spread of transmissible spongiform encephalopathies between humans have yet been
reported. The iatrogenic transmission of prion diseases by instruments that have come into
contact  with  the  nasal  mucosa  is  still  a  possibility  that  warrants  more  research [87,88].
Moreover,  the  presence  of  PrPsc in  the  urine  of  patients  with  vCJD  raises  major  health
concerns as regards its transmissibility. Since the incubation period of vCJD can vary from
years to decades [87], significantly more people than previously thought may well be infected,
but still in the presymptomatic phase of the disease. At the present time, the documented cases
of iCJD in the UK have been due to growth hormone replacement from cadavers, dura mater
grafts,  blood transfusion  and plasma transfusion  [89].  Furthermore,  transmission  of  prion
diseases  was  suspected  after  corneal  transplantation  and  the  use  of  contaminated
neurosurgical instruments and EEG electrodes [90-92].
The presence of PrPsc in numerous tissues of the body demands an answer to the question of
whether  prion  disease  can  be  transmitted  through  instruments  during  surgical  and  other
invasive  interventions.  A possibly  even  more  important  question  is  whether  CJD can  be
transmitted through airborne infection, direct contact with nasal discharge, urine, blood and
other bodily fluids, or even with sexual contact, in addition to the already proven transmission
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mechanisms of the acquired forms of prion diseases. In vCJD, it has been suggested based on
animal  models  that  after  oral  intake,  prion  proteins  are  transported  through the  intestinal
mucosa via M-cells [93]. Prion proteins can penetrate into the enteric nervous system, Peyer’s
patches and from there into other organs of the lymphoreticular system [94,95]. Prions can
then reach the brain via peripheral autonomic nerves: directly through the vagus nerve or by
reaching the spinal  cord via  sympathetic  nerves and then travelling cranially to  the brain
[96,97]. Banks et al. have suggested that the prion protein can cross the blood-brain barrier
[98].  Therefore,  after  transfusion of  blood from a CJD patient,  there is  a  possibility that
transfused prions can penetrate into the brain directly from the blood stream. Theoretically,
based on animal models, it is also possible that prion proteins can appear in the skin of those
who came in contact with bodily fluids of CJD patients [99]. From there, through cutaneous
nerves or the bloodstream, prion proteins might be able to penetrate into the CNS. Similarly,
in theory, airborne infection might be possible by accumulation of prions in the respiratory
organs and then spreading into the CNS via blood vessels or autonomic nerves supplying the
lungs, trachea, etc. During sexual contact, CJD patients might cause prion infection in the
reproductive organs of the partner. From these organs, prion proteins might be able to reach
the CNS via peripheral nerves or the blood stream. However, to date, no evidence of the
occupational transmission of CJD has been reported among health care workers, and infection
has  not  been  detected  after  direct  contact  with  body fluids  [100].  Nonetheless,  since  the
incubation period of acquired CJD can be so long, there well might be asymptomatic carriers
amongst us. They could even be blood or organ donors who are spreading the disease without
being aware of the potential devastating effect on others’ lives. The presymptomatic detection
of  the  disease  and  the  screening  of  blood  and organ  donors  is  therefore  clearly of  vital
importance. The two articles highlighted above give rise to the hope that medical science is on
the verge of detecting prion diseases before the development of symptoms. The questions
raised here could also apply to other NDs if their prion-like transmissibility is once proven.
The previous/current  and newly proposed transmission  mechanisms  of  prion  diseases  are
summarized in Table 5.
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